StonkScan
OverviewRevenueFinancialsValuationOutlookOwnership
Price
Performance · vs S&P 500
Company
Moderna, Inc.
NASDAQ · USD
Large cap
10% less volatile
Claude reads this page's data and writes up Moderna, Inc.'s financials, valuation and analyst coverage: built only from the figures here, with nothing pulled in from elsewhere.
Generated by an AI model from the data on this page. It can be wrong, and it isn't investment advice or a recommendation to buy or sell anything. Check every figure against the sections themselves before you rely on it.
$5.8B of cash and short-term investments against $1.2B of total debt.
Liquidity · FY25
$6.5B of current assets against $2.0B due within a year.
Liquidity · FY25
Revenue came in above consensus by 30.6% on average over the last four reports.
Quality · Jul '26
BioNTech and Moderna are no longer generating significant revenue from their coronavirus vaccines. Both have attractive pipelines that could lead to important new approvals over the next few years.
Moderna consolidates after a dramatic breakout, with a bullish pennant forming near resistance and offering a potential signal for another powerful advance.
MRNA's newly approved mFlusiva faces a potential challenge as GSK advances an mRNA flu vaccine targeting two viral proteins.
Rothschild analyst Simon Baker downgrades Moderna stock to Sell from Neutral while doubling his price target.
Tech giant Nvidia has remained ahead of rivals thanks to its competitive advantage. These healthcare companies have proven expertise in their fields -- and they would be difficult to unseat.
Markets wobble heading into the Labor Day weekend as bond vigilantes push back against Washington, oil stays tense with Middle East strikes escalating, and Wall Street analysts make bold calls on names ranging from Broadcom to Moderna that could reshape your portfolio positioning.
Average month-end to month-end move for MRNAin each calendar month. Point at a bar for that month's spread: past seasonality is a tendency in a small sample, not a forecast.
No live annual revenue history for MRNAright now: the data source didn't return it.
Share of the latest fiscal year, largest first. The line is the segment across every fiscal year we have: hover it to read one.
What each segment added to or took off the top line in dollars: ranked by the size of the move, not its percentage.
No live annual financials for MRNAright now: the data source didn't return it.
No live annual financials for MRNAright now: the data source didn't return it.
| $ billions | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Cash & equivalents | 2.6 | 1.9 | 2.9 | 3.2 | 6.8 |
| Short-term investments | 3.2 | 5.1 | 5.7 | 6.7 | 3.9 |
| Receivables | 0.3 | 0.6 | 1.1 | 1.7 | 3.3 |
| Inventory | 0.2 | 0.1 | 0.2 | 0.9 | 1.4 |
| Total current assets | 6.5 | 8.1 | 10.3 | 13.4 | 16.1 |
| Property, plant & equipment | 2.9 | 3.0 | 2.7 | 2.1 | 1.4 |
| Long-term investments | 2.3 | 2.5 | 4.7 | 8.4 | 6.8 |
| Other non-current assets | 0.6 | 0.6 | 0.7 | 1.9 | 0.4 |
| Total assets | 12.3 | 14.1 | 18.4 | 25.9 | 24.7 |
| Accounts payable | 0.3 | 0.4 | 0.5 | 0.5 | 0.3 |
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total current liabilities | 2.0 | 2.2 | 3.0 | 4.9 | 9.1 |
| Long-term debt | 1.2 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total liabilities | 3.7 | 3.2 | 4.6 | 6.7 | 10.5 |
| Shareholders’ equity | 8.7 | 10.9 | 13.9 | 19.1 | 14.1 |
Fiscal year · latest five reported years
No live cash-flow data for MRNAright now: the data source didn't return it.
No live valuation comparison data for MRNAright now: the data source didn't return it.
No live peer comparison data for MRNAright now: the data source didn't return it.
Dots = reported EPS vs consensus · gap = surprise · dashed = estimate ($)
Solid = reported · dashed = forward consensus · shaded = analyst low–high ($B)
No live DCF model data for MRNAright now: the data source didn't return it.
Last 12M · $16M bought · $48M sold · net −$32M